安悅國際(08245.HK)出售人壽保單予行政總裁料錄虧損322萬元
安悅國際(08245.HK)公布,間接全資附屬安悅以950萬元向執行董事兼行政總裁談永基出售匯豐人壽保險所承保的人壽保單,其投保金額為538.7萬美元。
目標資產原先由公司於2011年7月投購,並繳付一筆過保費100萬美元,現時的退保價值約為108.2萬美元。公司預期會錄321.7萬元虧損。所得款項淨額估計約938萬元,將會為中國境外的新生產設施提供支持、開發新產品及作為一般營運資金。
公司於2015年9月上市前,若干銀行融資以談永基提供的個人擔保作抵押,故相關銀行已要求安悅購入目標的資產作為要員保險,上市後,前述的個人擔保已由集團提供的公司擔保取代,持有目標的資產以滿足銀行融資的條件已不再適用。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.